+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Toxoplasmosis Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Toxoplasmosis

  • ID: 4629649
  • Report
  • September 2018
  • Region: Global
  • 65 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • Vyera Pharmaceuticals LLC
  • MORE
Toxoplasmosis Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Toxoplasmosis Infection pipeline products.

Report Description

The Toxoplasmosis Infection pipeline guide presents complete overview of drugs currently being developed for Toxoplasmosis Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Toxoplasmosis Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Toxoplasmosis Infection pipeline candidates is included.

Major companies participating in therapeutic development of Toxoplasmosis Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Toxoplasmosis Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Toxoplasmosis Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Toxoplasmosis Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Toxoplasmosis Infection pipeline report includes
  • Panorama of Toxoplasmosis Infection pipeline markets including statistics on therapeutic drugs and companies involved
  • Toxoplasmosis Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
  • Toxoplasmosis Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Toxoplasmosis Infection pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Toxoplasmosis Infection pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Toxoplasmosis Infection pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Toxoplasmosis Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Vyera Pharmaceuticals LLC
  • MORE
I. Key Findings

1. Companies Investing in Toxoplasmosis Infection Pipeline include-
Number of Companies with Toxoplasmosis Infection projects in pre-clinical Development-
Number of Companies with Toxoplasmosis Infection projects in Clinical Development-
Toxoplasmosis Infection Pipeline Companies based in Americas
Toxoplasmosis Infection Pipeline Companies based in Europe
Toxoplasmosis Infection Pipeline Companies based in Asia Pacific
Toxoplasmosis Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-
Toxoplasmosis Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Toxoplasmosis Infection Pipeline Agents in Clinical Development stage
Toxoplasmosis Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Toxoplasmosis Infection Pipeline agents

II. Insights into Toxoplasmosis Infection Pipeline -

1. Disease Overview
Introduction to Toxoplasmosis Infection
Symptoms and Causes of Toxoplasmosis Infection
Treatment or Prevention Options for Toxoplasmosis Infection
Other Details
2. Phase wise Pipeline Compounds
Toxoplasmosis Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Toxoplasmosis Infection Pipeline- Phase 1 stage Drugs
Toxoplasmosis Infection Pipeline- Phase 2 stage Drugs
Toxoplasmosis Infection Pipeline- Phase 3 stage Drugs
Toxoplasmosis Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Toxoplasmosis Infection Pipeline Compounds
4. Toxoplasmosis Infection Pipeline by Mechanism of Action

III. Toxoplasmosis Infection Pipeline Compound Details
  • CDPK1 inhibitor
  • Pyrimethamine
  • TUR-006
Drug Details

1. Snapshot-
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Toxoplasmosis Infection Pipeline Company Briefs
  • AbbVie Inc
  • GlaxoSmithKline Plc
  • Vyera Pharmaceuticals LLC
V. Latest News and Developments in Global Toxoplasmosis Infection Pipeline Market

VI. Appendix
1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability"
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Vyera Pharmaceuticals LLC
Note: Product cover images may vary from those shown
Adroll
adroll